VANCOUVER, British Columbia, Sept. 02, 2024 (GLOBE NEWSWIRE) -- Novo Resources Corp. (Novo or the Company) (ASX: NVO) (TSX: NVO) (OTCQX: NSRPF) is pleased to advise that the Company’s Executive Co-Chairman and Acting Chief Executive Officer Mike Spreadborough will present at the Resources Rising Stars Gold Coast Investor Conference, being held on Tuesday 3rd and Wednesday 4th September 2024. Mike will provide an update on the Company’s current and future exploration programs across Novo’s highly prospective ...

This competitive showdown just saw one of the players hit a couple of bumps.Eli Lilly (LLY 2.11%) and Novo Nordisk (NVO 1.19%) are big pharma peers. They're also each other's biggest rivals, especially in the all-important market for weight-loss drugs, in which both are currently highly successful.Right now, there are a few reasons to believe that Eli Lilly has the upper hand in this competitive clash. Those reasons support buying its stock, assuming you don't want to invest in both companies. Here are thre ...

The addressable market for the treatments could potentially contract significantly.Novo Nordisk's (NVO 2.26%) GLP-1 medicines, Ozempic and Wegovy, are bestsellers and household names. Whereas Ozempic is indicated for type 2 diabetes, Wegovy is prescribed for weight loss in the context of obesity. But, if some new information holds true, the company could soon see its presence in both of those markets take a hit.Here's what was just discovered and why it matters.This potential side effect needs urgent invest ...

Shareholders don't have too much to fear -- yet.The diabetes medicine Ozempic has been a veritable cash cow for Novo Nordisk (NVO -1.22%). The company's revenue, earnings, and stock price have been on a tear in recent years -- and no single drug has contributed more to its performance than Ozempic.However, various potential headwinds have popped up that could disrupt Ozempic's progress. One of them is competition. Novo Nordisk's longtime foe in the diabetes market, Eli Lilly, developed Mounjaro, a diabetes ...

Novo Nordisk still expects to see a lot more growth in the second half.Novo Nordisk (NVO 0.64%) recently posted its latest earnings numbers, and they fell short of Wall Street's expectations. Investors had high hopes for the company, which is known for its popular diabetes treatment, Ozempic, and its weight loss drug, Wegovy. But they may be having second thoughts about its growth prospects and its ability to be a continually top-performing investment in light of its recent performance.Could this recent ear ...

The volatility that has rocked markets since the beginning of July might not be over just yet. August has proven to be extremely rocky. The unwinding of the carry trade in Japan, coupled with fears of a potential U.S. recession, have sent stocks plunging. And while many stocks have clawed back their losses, a lot of large-cap tech stocks are still down more than 10% in the past month.The benchmark S&P 500 index has declined 2% since the start of July, and the tech-heavy Nasdaq Composite index had fallen 9% ...

Novo Nordisk (NVO) reported lower-than-expected second-quarter 2024 results. The company’s earnings of 65 cents per American Depositary Receipt missed the Zacks Consensus Estimate of 71 cents. The miss can be attributed to significantly higher operational costs during the quarter.Revenues of $9.82 billion, despite a year-over-year increase, missed the Zacks Consensus Estimate of $9.91 billion.Novo Nordisk expects its sales to grow in 2024. However, the company has lowered its guidance for operating profit g ...

There's reason to believe some of its expected revenue will take longer to arrive.Surprisingly, the last couple of months have been a touch harder than anticipated for Novo Nordisk (NVO -2.68%). While it's still raking in cash from sales of its medications for type 2 diabetes and weight loss, it also hit a trio of bumps in the road. Is its stock still a buy, or is its momentum finally starting to peter out?When it rains, it poursThe company's earnings update for the first half of 2024 and a few of its recen ...

Investors seek growth stocks to capitalize on above-average growth in financials that help these securities grab the market's attention and produce exceptional returns. But finding a growth stock that can live up to its true potential can be a tough task.In addition to volatility, these stocks carry above-average risk by their very nature. Also, one could end up losing from a stock whose growth story is actually over or nearing its end.However, it's pretty easy to find cutting-edge growth stocks with the he ...

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. Do they really matter, though?Let's take a look at what these Wall Street heavyweights have to say about Novo Nordisk (NVO) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.Novo Nordisk currently has an ...